Denali Therapeutics Inc (DNLI)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Ryan J. Watts
Employees:
430
151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO, CA 94080
(650) 866-8548

Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Data derived from most recent annual or quarterly report
Market Cap 4.001 Billion Shares Outstanding136.678 Million Avg 30-day Volume 748.027 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.87
Price to Revenue31.0017 Debt to Equity0.0 EBITDA-387.827 Million
Price to Book Value3.2539 Operating Margin-389.3646 Enterprise Value1.857 Billion
Current Ratio3.389 EPS Growth-0.226 Quick Ratio3.295
1 Yr BETA 1.5084 52-week High/Low 39.43 / 20.76 Profit Margin-365.209
Operating Cash Flow Growth0.7927 Altman Z-Score3.1325 Free Cash Flow to Firm -244.659 Million
Earnings Report2023-08-07
View SEC Filings from DNLI instead.

View recent insider trading info

Denali Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding DNLI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DNLI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-17 by SCHUTH ALEXANDER O.
  • 4: filed on 2023-04-24 by WATTS RYAN J.
  • 4: filed on 2023-04-14 by SCHUTH ALEXANDER O.
  • 4: filed on 2023-02-15 by KROGNES STEVE E.
  • 4: filed on 2023-02-15 by SCHUTH ALEXANDER O.
  • 4: filed on 2023-02-15 by WATTS RYAN J.
  • 4: filed on 2023-02-14 by HO CAROLE
  • 4: filed on 2023-02-13 by WATTS RYAN J.
  • 4: filed on 2023-02-10 by HO CAROLE
  • 4: filed on 2023-02-10 by SCHUTH ALEXANDER O.

    • Events (8k)

  • 8-K: filed on 2023-02-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-20:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-18:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-05:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-06-03:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-15:
  • 144: filed on 2023-04-20:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    45 Thousand total shares from 6 transactions

    Exercise Derivative Conversion (M)

    45 Thousand total shares from 5 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SCHUTH ALEXANDER O. COFO AND SECRETARY

    • Officer
    		 659,483 2023-05-15 11

    WATTS RYAN J. PRESIDENT AND CEO

    • Officer
    • Director
    		 4,668,263 2023-04-20 6

    HO CAROLE CHIEF MEDICAL OFFICER

    • Officer
    		 327,558 2023-02-15 9

    KROGNES STEVE E.

    • Director
    		 993,002 2023-02-13 5

    TESSIER-LAVIGNE MARC

    • Director
    		 2,107,225 2022-11-23 7

    FLATLEY JAY T

    • Director
    		 336,313 2022-06-02 1

    SATO VICKI L

    • Director
    		 160,108 2022-06-02 1

    KLEIN PETER S

    • Director
    		 29,272 2022-06-02 1

    COLE DOUGLAS G.

    • Director
    		 40,307 2022-06-02 1

    SCHENKEIN DAVID P

    • Director
    		 68,777 2022-06-02 1

    COOK JENNIFER E.

    • Director
    		 29,272 2022-06-02 1

    THORNBERRY NANCY

    • Director
    		 26,456 2022-06-02 1

    HARRIS ERIK

    • Director
    		 0 2022-02-07 0

    NELSEN ROBERT

    • Director
    		 9,681,181 2021-06-02 0

    BRATTON DOUGLAS K

    AKDL, L.P.

    CRESTLINE SI (GP), L.P.

    CRESTLINE INVESTORS, INC.

    CRESTLINE MANAGEMENT, LP

    • 10% Owner
    		 No longer subject to file 2021-02-12 0

    BRATTON DOUGLAS K

    NEURO LINE PARTNERS LP

    BRATTON CAPITAL MANAGEMENT, L.P.

    BRATTON CAPITAL INC.

    • 10% Owner
    		 12,201,634 2020-12-21 0

    BIOGEN INC.

    BIOGEN MA INC.

    • 10% Owner
    		 13,310,243 2020-09-22 0

    ARCH VENTURE FUND VIII, L.P.

    ARCH VENTURE PARTNERS VIII, L.P.

    ARCH VENTURE PARTNERS VIII, LLC

    BYBEE CLINTON

    CRANDELL KEITH

    • 10% Owner
    		 10,668,749 2019-08-08 0

    SCHUTH ALEXANDER O. COO AND SECRETARY

    SCHUTH ALEXANDER O. COO AND SECRETARY

    • Officer
    		 686,565 2019-03-11 11

    FMR LLC

    • SEE REMARK 1
    		 No longer subject to file 2018-04-09 0

    FIL LTD

    • SEE REMARK 1
    		 No longer subject to file 2017-12-12 0

    FLAGSHIP VENTURES FUND V, L.P.

    AFEYAN NOUBAR

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    • 10% Owner
    		 No longer subject to file 2017-12-12 0

    BRATTON DOUGLAS K

    AKDL, L.P.

    NEURO LINE PARTNERS LP

    CRESTLINE SI (GP), L.P.

    CRESTLINE INVESTORS, INC.

    BRATTON CAPITAL MANAGEMENT, L.P.

    BRATTON CAPITAL INC.

    CRESTLINE MANAGEMENT, LP

    • 10% Owner
    		 20,574,298 2017-12-12 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY see footnote

    		2023-05-17 16:56:57 -0400 2023-05-15 S 800 $29.23 d 528,691 indirect yes 4.0527 -1.7792 5.3048 4 -1.7792 6

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY see footnote

    		2023-05-17 16:56:57 -0400 2023-05-15 S 9,200 $28.55 d 529,491 indirect yes 4.0527 -1.7792 5.3048 4 -1.7792 6

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY see footnote

    		2023-05-17 16:56:57 -0400 2023-05-15 M 10,000 $5.28 a 538,691 indirect 4.0527 -1.7792 5.3048 4 -1.7792 6

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY

    		2023-05-17 16:56:57 -0400 2023-05-15 M 10,000 d 78,937 direct

    WATTS RYAN J. - Director - Officer PRESIDENT AND CEO see footnote

    		2023-04-24 19:10:38 -0400 2023-04-21 M 24,800 $0.68 a 2,264,713 indirect 2.0092 2.0511 7.995 5 0.0 1

    WATTS RYAN J. - Director - Officer PRESIDENT AND CEO see footnote

    		2023-04-24 19:10:38 -0400 2023-04-21 S 24,800 $25.15 d 2,239,913 indirect yes 2.0092 2.0511 7.995 5 0.0 1

    WATTS RYAN J. - Director - Officer PRESIDENT AND CEO

    		2023-04-24 19:10:38 -0400 2023-04-21 M 24,800 d 1,170,617 direct

    WATTS RYAN J. - Director - Officer PRESIDENT AND CEO see footnote

    		2023-04-24 19:10:38 -0400 2023-04-20 M 200 $0.68 a 2,240,113 indirect 2.0092 2.0511 7.995 5 0.0 1

    WATTS RYAN J. - Director - Officer PRESIDENT AND CEO see footnote

    		2023-04-24 19:10:38 -0400 2023-04-20 S 200 $25.00 d 2,239,913 indirect yes 2.0092 2.0511 7.995 5 0.0 1

    WATTS RYAN J. - Director - Officer PRESIDENT AND CEO

    		2023-04-24 19:10:38 -0400 2023-04-20 M 200 d 1,195,417 direct

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY see footnote

    		2023-04-14 18:27:13 -0400 2023-04-13 M 4,898 $5.28 a 533,589 indirect -1.6445 -2.3101 14.6045 25.372 21 -6.4605 7

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY see footnote

    		2023-04-14 18:27:13 -0400 2023-04-13 S 4,898 $25.04 d 528,691 indirect yes -1.6445 -2.3101 14.6045 25.372 21 -6.4605 7

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY

    		2023-04-14 18:27:13 -0400 2023-04-13 M 4,898 d 88,937 direct

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY see footnote

    		2023-04-14 18:27:13 -0400 2023-04-12 M 5,102 $5.28 a 533,793 indirect -1.6445 -2.3101 14.6045 25.372 21 -6.4605 7

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY see footnote

    		2023-04-14 18:27:13 -0400 2023-04-12 S 5,102 $25.04 d 528,691 indirect yes -1.6445 -2.3101 14.6045 25.372 21 -6.4605 7

    SCHUTH ALEXANDER O. - Officer COFO AND SECRETARY

    		2023-04-14 18:27:13 -0400 2023-04-12 M 5,102 d 93,835 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    DENALI THERAPEUTICS INC DNLI 2023-05-31 22:15:04 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 21:45:04 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 21:15:03 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 20:45:04 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 20:15:06 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 19:45:04 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 19:15:21 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 18:45:03 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 18:15:04 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 17:45:03 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 17:15:05 UTC 4.81 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 16:45:04 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 16:15:04 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 15:45:03 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 15:15:04 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 14:45:04 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 14:15:03 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 13:45:04 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 13:15:04 UTC 4.82 0.25 1500000
    DENALI THERAPEUTICS INC DNLI 2023-05-31 12:45:04 UTC 4.82 0.25 1500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund DNLI -2024.0 shares, $-64565.6 2020-08-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund DNLI -330.0 shares, $-5778.3 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund DNLI -24.0 shares, $-420.24 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund DNLI -325.0 shares, $-5690.75 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments